Analyst Michael Matson of Needham reiterated a Buy rating on Boston Scientific, boosting the price target to $121.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong performance and future potential. The company exceeded expectations in its second-quarter 2025 revenue and earnings per share, prompting management to increase their guidance for the year. Despite a slight slowdown in organic growth as the company fully laps the FARAPULSE launch, the FARAPULSE and WATCHMAN products continue to be significant growth drivers for Boston Scientific.
Moreover, while the gross margin experienced a slight decline due to inventory charges, the operating margin improved, showcasing effective cost management. The company also adjusted its 2025 tariff expectations downward, indicating confidence in offsetting these costs through enhanced revenue growth and reduced spending. These positive developments have led to an increased price target, reinforcing the Buy rating as Boston Scientific’s key growth drivers continue to perform well.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $127.00 price target.
Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.